Norrsken EvolveTHE DEAL, AT A GLANCE
1/4 reviewedTolemy Bio
Tolemy Bio
Tolemy develops virtual cell tools to help direct living cells used in developing and manufacturing medicines.
Tolemy Bio raised Pre-Seed, announced 2026-11-13What it doesTolemy develops virtual cell tools to help direct living cells used in developing and manufacturing medicines.Source-grounded · automated review · Explore ↗
Checked 2026-11-13 · Review due 2026-11-20
Read supporting source ↗The AI-native virtual cell platform…
Who is involvedBacked by Norrsken Evolve, Big Sur Ventures, JME Ventures, MasiaFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗What happenedTolemy Bio raised Pre-Seed, announced 2026-11-13From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Why it mattersTolemy Bio raised €1.4 million in a pre-seed round to develop its Orbit platform and support early customer and partner deployments.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗
Tolemy Bio · Financing Record
Explore source-linked visual explanations for Tolemy Bio. Unsupported claims are withheld while source review continues.
Record 15938 · Recorded date: 2026-11-13
Explore company records →